Navigation Links
Minneapolis Heart Institute Foundation welcomes Europace publication of Optim lead insulation paper
Date:8/21/2012

MINNEAPOLIS, MN August 21, 2012 The Minneapolis Heart Institute Foundation, an international leader in cardiovascular research, today announces the online publication of a study in EP Europace that raises serious concerns about St. Jude Medical defibrillator leads. The study found that a new copolymer of silicone and polyurethane (Optim) might not prevent insulation abrasions that can result in electronic malfunction. The paper is authored by Foundation researchers Robert Hauser, Raed Abdelhadi, Deepa McGriff and Linda Retel, and it is another in a series of Foundation publications that have reported significant problems with defibrillator leads, including recalled Riata and Riata ST leads from St. Jude Medical (SJM).

Defibrillators are implanted in patients to prevent sudden cardiac death.

Defibrillator leads deliver energy to the heart in order to stop abnormal, rapid heartbeats that can cause blackouts and death. These leads must be able to function properly during years of service in the body.

The paper "Failure of a Novel Silicone-Polyurethane Copolymer (Optim) to Prevent ICD Lead Insulation Abrasions" appears on the journal's web site and is available at http://europace.oxfordjournals.org/content/current.

"Our paper presents data that suggest Riata ST Optim and Durata ICD leads may not be adequately protected from insulation abrasions caused by friction with the pulse generator can or other leads in the heart," stated Dr. Hauser. "We need studies to determine the incidence of these failures and the implications for patients. At this time we do not believe that patients should be unduly concerned or their leads replaced. We do believe that patients with these leads should be evaluated regularly, as recommended by their physicians."

This study follows on the heels of a recent FDA order that St. Jude Medical launch new studies focusing on the performance of its Riata and Duranta defibrillator leads.

"We know new leads need to be implanted for years before useful reliability data can be collected," stated Dr. Hauser. "We are still in the process of gathering information about Optim, so these are not definitive data, and at this point in time we do not see a direct risk to patients."

The purpose of this study was to determine if Optim, a unique co-polymer of silicone and polyurethane, protects Riata ST Optim and Durata implantable cardioverter-defibrillator leads from abrasions that cause lead failure. The FDA's Manufacturers and User Device Experience (MAUDE) database search returned 15 reports for Riata ST Optim and 37 reports for Durata leads, which were submitted by SJM based on its analyses of returned leads for clinical events that occurred between December 2007 and January 2012. Eight of 15 Riata ST Optim leads had can abrasions and 3 abrasions were caused by friction with another device, most likely another lead. Twelve Durata leads had can abrasions, and six leads had abrasions caused by friction with another device. The paper concludes that Riata ST Optim and Durata ICD leads have failed due to insulation abrasions and that Optim did not prevent these abrasions, which developed up to four years after implant. The paper recommends that studies are needed to determine the incidence of these failures and their clinical implications.


'/>"/>
Contact: Steve Goodyear
sgoodyear@mhif.org
612-863-1658
Minneapolis Heart Institute Foundation
Source:Eurekalert

Related medicine news :

1. Former Vikings and NFL Greats Tackle Sleep Apnea at Upcoming Minneapolis Event
2. Minneapolis Heart Institute Foundation welcomes Europace publication of Optim™ lead insulation paper
3. Witnessing, Experiencing Traumatic Events May Worsen Heart Disease
4. Risk of suicide and fatal heart attack immediately following a cancer diagnosis
5. Cancer Diagnosis May Raise Odds for Suicide, Heart Attack Death
6. In children born with severe heart defect, surgical management has little effect on neuro outcomes
7. Invasive heart test being dramatically overused, Stanford study shows
8. Heart failure patients with diabetes may benefit from higher glucose levels
9. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
10. EKG Heart Test May Predict Risk in Older Adults
11. Common Blood Pressure Drug Safe for Heart Failure: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... ... January 07, 2020 , ... CBD For The People ... keeping the focus on the individual customer service experience. Transparency and integrity are the ... the profits second. By taking care of the people first, they know that satisfied ...
(Date:1/7/2020)... ... ... Iconic singer, choreographer and actress Paula Abdul isn’t just known for ... all time, but also for looking absolutely flawless in her 50s. At 57 years ... to making it through 10 hour rehearsals and aging gracefully. While stretching, pilates, eating ...
(Date:1/7/2020)... ... January 06, 2020 , ... MemoryCare.com ... has announced the Best Memory Care Facilities in Lakeland, Florida. The guide identifies ... amenities. , According to the Alzheimer’s Association , 5.6 million people ...
(Date:1/7/2020)... ... January 07, 2020 , ... R3 Stem ... includes comprehensive presentations and procedures for hair restoration, facial rejuvenation and sexual wellness. ... , Regenerative aesthetics has become incredibly popular over the past few years as ...
(Date:1/7/2020)... ... January 07, 2020 , ... MMJ International Holdings, the ... for ?Orphan Drug Designation? for its THC and CBD proprietary drug formulation which will ... MMJ’s lead drugs and the company is confident that it will bring much needed ...
Breaking Medicine News(10 mins):
(Date:1/12/2020)... , ... January 12, 2020 , ... ... Johnson & Johnson Innovation - JJDC, and Takeda Ventures, Inc, operating under a ... company – Epeius Pharma in collaboration with Ramot at Tel-Aviv University and Glasgow ...
(Date:1/10/2020)... ... January 10, 2020 , ... Mymee, a digital care program aimed ... website. The new website features real client success stories, a simplified description ... cost-reduction outcomes to self-insured employers and payers. , “There were two key drivers ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... now able to accept Medicare for medication-assisted treatment services at their Opioid ... and naltrexone, all FDA-approved medications, as well as counseling, began on January ...
Breaking Medicine Technology: